Sat, Apr 19, 2014, 3:55 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

jetmanbash 605 posts  |  Last Activity: 2 hours 30 minutes ago Member since: Dec 29, 2004
  • Reply to

    Eye opening information,

    by tnorman61 Apr 11, 2014 12:48 PM
    jetmanbash jetmanbash 2 hours 30 minutes ago Flag

    When are the earnings coming out? And what are your predictions? What is the chances that earnings will have to be restated after FDA penalities, lawyer fees, and fees for defending themselves from the Brazil accusations. I don't think GKS will ever buy them out as GSK has its own around the world accusations for bribery. t

  • jetmanbash by jetmanbash Apr 15, 2014 8:52 AM Flag

    VICL has enjoyed none of biotechs big run over the last two years and now it "enjoys" biotech's huge fall. A testament to the CEO and their "safe" drug for dog mouth melanoma. As a public service from the people at VNN: please check your dog's mouth daily for hints of dog mouth melanoma as there is now a big selling safe drug on the market for it by your favorite biotech VICL. If caught early and you use this drug you may be able to treat your dog better than any placebo out there for it. Also, recent literature seems to show that letting your dog drink beer can increase your dog's risk of doggy mouth melanoma. t

  • Reply to

    Eye opening information,

    by tnorman61 Apr 11, 2014 12:48 PM
    jetmanbash jetmanbash Apr 15, 2014 1:26 AM Flag

    AEGR had its carnage over the previous four months. ZAP3 coming soon, Mr. Beer should another study to see how many people on the moon have HoF. Also, he could check and see how many low-land gorillas have it too. t

  • Reply to

    Open your Eyes to Aegerion...

    by aniustudent Apr 11, 2014 1:42 PM
    jetmanbash jetmanbash Apr 15, 2014 1:23 AM Flag

    Xanax should be used in panic attacks and generalized anxiety disorder, not depression. Xanax doesn't cost $This company has missed on every earnings projection since its existence. The DB analyst has a 105 target, the Yugo has a 1200-6400 target. We'll see if this expensive one trick pony can deliver......I bet not. t

  • jetmanbash jetmanbash Apr 15, 2014 1:15 AM Flag

    Here VNN we have noted with interest that VICL is 11 cents away from a yearly low when you had said it was VICL's turn to go up. Not looking good for VICL. Short-term target 94 cents, long term target BK. t

  • jetmanbash by jetmanbash Apr 13, 2014 11:36 PM Flag

    Is 84 cents. Only 13 cents away from 52 week low. Here at VNN we are looking for VICL to drop to the bottom 10% of biotech companies. t

  • jetmanbash by jetmanbash Apr 12, 2014 6:39 PM Flag

    Long term goal is to acquire 100K shares and hold for three to four years with a target of between $17.5 abd $25. The CEO has together and I believe the company will succeed. t

    Sentiment: Strong Buy

  • Reply to

    Latest from VNN:

    by jetmanbash Apr 11, 2014 9:02 AM
    jetmanbash jetmanbash Apr 11, 2014 9:08 AM Flag

    We at VNN rate the chances for a reverse split to try and get the stock over $5 about 69%. How else will the CEO be able to try and lie to MM's about the stock and sell them shares? Worst CEO in biotech history.....maybe. t

  • jetmanbash by jetmanbash Apr 11, 2014 9:02 AM Flag

    Vical now only 17 cents from year low. This despite a mini-buying spree by the CEO who continued to treat patients despite probably knowing that the treatment was worse for them than the placebo treatment. If the biotech onslaught continues we predict new yearly lows for VICL very soon. Stock rated DSPB......meaning double secret probation for bankruptcy. t

  • Reply to

    The Trials are Over Jetmanbash - Get Over It...

    by aniustudent Apr 9, 2014 12:50 AM
    jetmanbash jetmanbash Apr 9, 2014 10:34 AM Flag

    The product name in Japan should be ugopoopoo. Or in honor of our very own Yugo, yugopoopoo. t

  • Reply to

    The Trials are Over Jetmanbash - Get Over It...

    by aniustudent Apr 9, 2014 12:50 AM
    jetmanbash jetmanbash Apr 9, 2014 10:27 AM Flag

    I say invest away to your heart's content. We'll see how things go over the next year. There are so many other biotechs with real platforms, and honest management in the 40 dollar price range, SGEN for example, that this one drug dog with a 20 year pill is a really bad investment. t

  • jetmanbash jetmanbash Apr 8, 2014 7:58 PM Flag

    A one person study on the excellent safety profile of juxtapid??

  • jetmanbash jetmanbash Apr 8, 2014 7:31 PM Flag

    VNN has gotten an exclusive list of upcoming really legitimate vaccine companies.......VICL didn't make the list:((

    http://finance.yahoo.com/news/biotech-market-could-quadruple-3-133000076.html

  • jetmanbash by jetmanbash Apr 7, 2014 11:48 PM Flag

    The drug for Dengue Fever that VICL has is far behind the one from TKMR. It is still in preclinical trials. Moreover, the drug from TKMR appears to be extremely effective. Thus we have come to the conclusion that VICL really only has four viable drugs in their pipeline after 20 years of drug discovery attempts. Two failures in a row will doom the company. There is also plenty of competition in regards to CMV. We have to lower our viability rating on VICL to yellow.....two failures away from non existence. t

  • Also please note that we here at VNN know that a lot of you are pet owners and are concerned about your dog developing oral melanoma. We have a firm conviction to keep you informed about VICL's vaccine to treat canines for this terrible disease. We also are looking at other products like a dog lip balm, and doggy food that contains UV A and UV B protection for your dog's mouth, as well as chewys that do the same thing. Rest assured while you are over trying to get new recruits for a VICL investment, we will be keeping a close eye on developments that could save your dog's......FILM AT 11. t

  • Reply to

    Vical at 1.24 cents

    by outtinfront Apr 4, 2014 1:20 PM
    jetmanbash jetmanbash Apr 6, 2014 8:34 PM Flag

    VICL will have to go up 200% just to approach their 52 week high. They only really two products on the horizon that could do anything. Everything else is back pretty far. INO, and AGEN are probably better companies. Watch out if there is another delay in their clinical lab results like last time when the patients on placebo actually did worse and some people were rumoring the CEO could face assault charges based on that. They have really underperformed by magnitudes compared to ISIS if you take your starting reference point from the 1996 article. That funny virulent guy is going to a real cheerleader.....Gooooooo Vical? Score a basket without your products going into one. The VNN will continue to give updates as we see them. So far that it is like Bugtussel, not much going on there. God bless 'em, they'll need it with the past record, diminishing cash, weak pipeline, using vaccines that are hard to really get on the market.......How many drug vaccines are there on the market besides that huge winner from DNDN?? And then once, or maybe twice five years later you will need another vaccine if the first one didn't kill you. Also, the internet will hurt them as there are people out there that believe that all vaccines are bad. Don't think so?? Take a look at the epidemic in Washington state, and CA in regards to whooping cough after the internet fleeced all legitimacy out of vaccines with their propaganda. As unfair as it is, it is what it is. The VNN is there right beside you Macro/Micro, ac/dc and all others as you go through bankruptcy. t

  • Reply to

    Vical at 1.24 cents

    by outtinfront Apr 4, 2014 1:20 PM
    jetmanbash jetmanbash Apr 6, 2014 8:24 PM Flag

    The three stocks that are fairly well known that have the highest risk of going to zero IMO are VICL, DNDN, and AEGR. Not say they will, but one misstep and they will be gone. All three are on double secret probation in regards to the big rules of the game. t

  • jetmanbash jetmanbash Apr 6, 2014 8:20 PM Flag

    You stereotype and you don't have too much of a biological background. Go to betting on sports. t

  • jetmanbash jetmanbash Apr 6, 2014 4:36 PM Flag

    I'd call ISIS and ask to speak to their head of toxicology and demand to know the liver fat numbers on most patients after 7 months of use of Kynamro. As cousin Ester will tell you the truth will set you free. So how many patients on juxta on a higher dose than 20mg per day. How many patients on a higher dose have a lowering of their liver fat after five or six half-lifes transpire? How many on juxta get fatty infilltration of the small intestine? What are the ramifiactions for that.....come people someone should know. Will that increase the amount of malabsorption? Should all patients have a trace mineral panel drawn every year? Are trace minerals like Zinc important? Does the rate of inflammatory bowel disease increase with this fatty infiltration of the small intestine? Does the risk of Clostridium difficle increase with this fatty infiltration of the small intestine? Does a person have to have such high doses of Vitamin D repletion that it increases their risk of developing atrial fibrillation? What is the cost over a life of taking the drug in regards to extraneous costs compared to the competition? Dollar for dollar is it the best bet? 23 patients in less than two years study and some people have all of the answers......but they aren't the ones prescribing the med, so no matter how someone wants to talk about compassionate use, if a child uses the drug and dies from it from off-label use they will be liable and have to at least face a lawsuit, not all lawsuits are won by the plaintiff, but parents who allow their kids to be put on the drug need to go in with eyes wide open, and not like Mr. Beer projected on Fast Money. t

ISIS
34.01-0.56(-1.62%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.